[Gemcitabine and urogenital tumors]

Among genito-urinary tumors, gemcitabine has only got the marketing approval for advanced urothelial cancer. The combination of gemcitabine and cisplatin has been shown to be a new standard of treatment in this disease because of equal efficacy and lesser toxicity as compared to the classic M-VAC protocol which includes methotrexate, vinblastin, doxorubicin and cisplatin. However new trials are required with the aim of improving survival, especially in the adjuvant setting after cystectomy. The role of gemcitabine in other tumors of the genito-urinary tract has to be determined.